References

1. Gelmon KA, Boyle F, Kaufman B, et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol. 2012;30(suppl; abstr LBA671).


Continue Reading

2. Clinicaltrials.gov. Chemotherapy and lapatinib or trastuzumab in treating women with HER2/neu-positive metastatic breast cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00667251. Accessed June 21, 2012.

3. Guan Z-z, Xu B-h, Arpornwirat W, et al. Overall survival benefit observed with lapatinib (L) plus paclitaxel (P) as first-line therapy in patients with HER2-overexpressing metastatic breast cancer (MBC). Poster presented at: 2010 CTRC-AACR San Antonio Breast Cancer Symposium; December 10, 2010; San Antonio, TX. P3-14-24.

4. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-2743.

5. [email protected] FDA Approved Drug Products. Tykerb (lapatinib ditosylate). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed June 21, 2012.

6. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26(34):5544-5552.


HOW TO TAKE THE POST-TEST: To obtain CME credit, please click here after reading the article to take the post-test on myCME.com.